Observational study finds right ventricular dysfunction predicts worse outcomes in heart failure patients — Evidence Review

Millions may be living with a hidden form of heart failure that is difficult to diagnose, but a new study finds that right ventricular dysfunction in these patients is a strong predictor of worse outcomes. Related studies broadly support these findings, highlighting the prognostic importance of right heart function and its frequent involvement in heart failure with preserved ejection fraction (HFpEF), as detailed in the original study from the University of Wisconsin–Madison.

• Multiple large-scale analyses confirm that right ventricular dysfunction and pulmonary hypertension are common in HFpEF and independently predict mortality and hospitalization, emphasizing the need for improved phenotyping and earlier detection 2 3 5.
• The focus on right ventricular impairment aligns with existing research suggesting that conventional treatments for pulmonary hypertension in HFpEF often fail, possibly due to underlying heterogeneity in disease mechanisms 1 2.
• The identification of cellular energy metabolism changes, particularly mitochondrial dysfunction, as a molecular correlate of right ventricular failure, builds upon prior evidence suggesting metabolic dysregulation contributes to HFpEF pathophysiology 2 3.

Study Overview and Key Findings

Heart failure with preserved ejection fraction (HFpEF) is increasingly prevalent, particularly among older adults, women, and those with comorbidities such as hypertension, diabetes, and obesity. Despite its rising incidence, HFpEF often goes undetected until advanced stages, partly because traditional diagnostic tools focus on left ventricular function, missing right-sided involvement. This new study sought to clarify the clinical and molecular features of HFpEF compounded by pulmonary hypertension (PH-HFpEF), exploring why some patients experience severe breathlessness and poor outcomes while others do not.

Property	Value
Organization	University of Wisconsin–Madison, Morgridge Institute for Research
Journal Name	Circulation: Heart Failure
Authors	Farhan Raza, Wei Guo
Population	Patients with heart failure with preserved ejection fraction
Sample Size	48 patients
Methods	Observational Study
Outcome	Right ventricular function, hospitalization rates, mortality
Results	Right ventricular dysfunction predicted worse outcomes.

Literature Review: Related Studies

To understand how these findings fit into the broader context, we searched the Consensus database of over 200 million research papers using the following queries:

1. right ventricular dysfunction heart failure outcomes
2. hidden heart failure prevalence studies
3. breathlessness heart failure management strategies

Summary Table of Related Literature

Topic	Key Findings
What is the prognostic significance of right ventricular dysfunction in HFpEF?	- RV dysfunction is highly prevalent in HFpEF and independently predicts mortality and hospitalization 2 3 5. - RV function is a stronger predictor of outcomes than left ventricular measures in multiple heart failure populations 2 3 4 5.
How common is hidden or undiagnosed HFpEF in the general population?	- HFpEF is frequently underdiagnosed, especially in older adults and individuals with diabetes, with studies showing most cases are previously unrecognized 7 8 10. - Population studies estimate HFpEF affects up to one in six adults over 50, with higher prevalence in women and older individuals 6 9 10.
What are the mechanisms and clinical implications of breathlessness in HFpEF?	- Breathlessness is a primary and often underreported symptom in HFpEF, with significant impact on quality of life and prognosis 13 14. - Management remains challenging, with limited evidence for pharmacological relief and a need for individualized, non-pharmacological approaches as first-line treatments 11 12 15.
Are there molecular or metabolic pathways implicated in right-sided heart failure?	- Disrupted mitochondrial energy metabolism and altered RNA processing have been proposed as underlying mechanisms in HFpEF and right ventricular dysfunction 2 3. - Identifying these pathways may enable more precise therapeutic targeting and could explain why broad treatments for pulmonary hypertension in HFpEF have had limited success 1 2.

What is the prognostic significance of right ventricular dysfunction in HFpEF?

Research consistently demonstrates that right ventricular (RV) dysfunction is both common and clinically significant in HFpEF. The new study's finding that RV dysfunction predicts worse outcomes closely aligns with a substantial body of evidence showing that RV impairment is a strong, independent predictor of mortality and hospitalization in heart failure populations, including those with preserved ejection fraction 2 3 5. The literature further suggests that RV function may outperform traditional left ventricular measures for risk stratification.

• Several large meta-analyses and cohort studies find that RV dysfunction occurs in 18–33% of HFpEF patients and is associated with increased risk of death 2 3 5.
• Measures such as tricuspid annular plane systolic excursion (TAPSE) and fractional area change (FAC) are used to quantify RV function and consistently predict adverse outcomes 2 3 4 5.
• RV dysfunction develops in response to increased pulmonary pressures and is exacerbated by comorbidities like atrial fibrillation and male sex 3 5.
• The new study builds on this by correlating RV impairment with molecular changes, suggesting a potential mechanistic link 2 3.

How common is hidden or undiagnosed HFpEF in the general population?

HFpEF is widely recognized as an underdiagnosed condition, particularly among older adults and people with diabetes. The new study's emphasis on the difficulty of early detection is echoed by research showing high rates of previously unknown heart failure in the community, often with subtle or atypical symptoms.

• Studies in older adults and those with diabetes find that 17–23% may have undiagnosed HFpEF, with prevalence increasing sharply with age and comorbidities 7 8 10.
• The PORTHOS study found that over 90% of HF cases in adults aged ≥50 were HFpEF, and most were previously unrecognized 10.
• Heart failure prevalence rises from about 4.5% in those over 50 to 10% in those over 70 9.
• Early recognition and screening, especially using natriuretic peptides and echocardiography, are recommended to address this diagnostic gap 10.

What are the mechanisms and clinical implications of breathlessness in HFpEF?

Breathlessness is the hallmark symptom in HFpEF but is often underappreciated or dismissed, leading to delays in diagnosis and management. Studies emphasize the profound impact of breathlessness on daily life, the importance of patient self-management strategies, and the limited efficacy of current pharmacological interventions.

• Qualitative research shows that breathlessness affects daily activities, emotional well-being, and often goes unreported or unnoticed by healthcare providers 13 14.
• Management strategies are primarily non-pharmacological; opioids and other medications have limited and sometimes questionable benefit for chronic breathlessness in heart failure 11 15.
• Patients often develop their own coping strategies, highlighting the need for better education and individualized care plans 12 13 14.
• The new study’s focus on symptom burden reinforces the need for early detection and tailored intervention 13 14.

Are there molecular or metabolic pathways implicated in right-sided heart failure?

Emerging evidence points to cellular energy metabolism, particularly mitochondrial dysfunction, as an important factor in the development and progression of right-sided heart failure. The new study identifies reduced mitochondrial function and altered RNA processing in patients with RV dysfunction, which is consistent with growing interest in metabolic contributors to HFpEF.

• Metabolic dysfunction, especially impaired mitochondrial energy production, has been implicated in both animal and human studies of HFpEF and right-sided heart failure 2 3.
• These findings may help explain why treatments targeting pulmonary vascular resistance alone have not improved outcomes in HFpEF with RV dysfunction 1 2.
• Identifying molecular subgroups could lead to more precise, targeted therapies, potentially improving clinical trial success rates 2 3.
• The study’s use of advanced RNA sequencing technologies highlights the role of genomic and transcriptomic profiling in understanding heart failure heterogeneity 2.

Future Research Questions

Although this study adds important insights into the role of right ventricular dysfunction and molecular drivers in HFpEF, further research is needed to address outstanding questions and improve patient outcomes. Key areas for future investigation include refining diagnostic strategies, exploring targeted therapies, and validating molecular phenotypes in larger, more diverse populations.

Research Question	Relevance
How can right ventricular function be more accurately assessed noninvasively in HFpEF?	Improved noninvasive assessment could enable earlier detection and risk stratification in HFpEF, potentially preventing progression to advanced disease 2 3.
What molecular subtypes of HFpEF exist and how do they respond to specific therapies?	Identifying and validating molecular subgroups may allow for precision medicine approaches, improving therapeutic effectiveness and trial outcomes 2 3.
Which patients with HFpEF and RV dysfunction benefit from current pulmonary hypertension treatments?	Trials to date have been disappointing; understanding which biological subgroups may benefit could guide therapy and clinical trial design 1 2.
What are the long-term outcomes of early screening for HFpEF in high-risk populations?	Early detection may improve prognosis, but its impact on morbidity and mortality needs to be established in large, prospective studies 7 8 10.
How does mitochondrial dysfunction contribute to right ventricular failure in HFpEF?	Understanding this mechanism could inform development of metabolic therapies and clarify links between molecular changes and clinical outcomes in HFpEF 2 3.

---

This article summarizes the current state of research on right ventricular dysfunction in HFpEF, highlighting key findings, connections to existing literature, and directions for future study. The challenge of early detection and the need for precision medicine approaches remain critical areas for advancing care in this growing patient population.